Rami Abazid | Clinical Trials | Research Excellence Award

Published on by Top Pharmaceutical

Dr. Rami Abazid | Clinical Trials | Research Excellence Award

Northern Ontario School of Medicine University | Canada

Dr. Rami Abazid is a distinguished cardiologist and academic leader recognized for his extensive expertise in advanced cardiovascular imaging and his long-standing contributions to clinical cardiology. He currently serves as an Assistant Professor at the Northern Ontario School of Medicine University and practices as a cardiologist at Sault Area Hospital in Ontario, Canada, where he is deeply engaged in delivering high-level patient care, mentoring trainees, and advancing imaging-based diagnostic excellence. Dr. Abazid’s professional journey reflects a progressive expansion of knowledge across multiple cardiology subspecialties, supported by a rich portfolio of prestigious board certifications, including cardiovascular CT, nuclear cardiology, echocardiography, and certifications from renowned institutions in internal medicine and cardiovascular diseases. His training includes high-level fellowships in echocardiography, cardiovascular CT, and nuclear cardiology, complemented by hybrid imaging training that strengthened his multidisciplinary approach to cardiac diagnostics. Throughout his career, he has practiced in several leading medical centers, holding roles such as consultant cardiologist, specialist, senior registrar, and fellow in cardiovascular medicine, which allowed him to cultivate mastery across inpatient care, emergency cardiac assessment, outpatient management, and complex imaging modalities. Dr. Abazid is well known for his proficiency in echocardiography, including transthoracic, transesophageal, three-dimensional and intraoperative imaging, as well as stress testing and structural heart assessments. His expertise extends to cardiovascular CT for coronary assessment, congenital heart evaluation, aortic imaging, TAVI planning, prosthetic valve analysis, and calcium scoring using advanced imaging platforms. Additionally, he is experienced in nuclear cardiology, including SPECT, PET, viability assessment, amyloid imaging, sarcoidosis evaluation, and various stress testing protocols. Dr. Abazid has held significant administrative and leadership roles, including chairing the cardiac CT unit and the cardiac outpatient department, while also serving on ethics committees and leading scientific abstract committees within major cardiology organizations. As an active member of international professional societies and a contributor to authoritative educational modules, he continues to influence the evolution of cardiovascular imaging practice worldwide. Driven by academic excellence, clinical precision, and a passion for innovation, Dr. Abazid remains a respected figure in modern cardiology, dedicated to advancing patient outcomes and shaping the next generation of cardiovascular specialists.

Profile: Google Scholar

Featured Publications

Stocker, T. J., Deseive, S., Leipsic, J., Hadamitzky, M., Chen, M. Y., Rubinshtein, R., … Abazid, R.
Reduction in radiation exposure in cardiovascular computed tomography imaging: Results from the PROspective multicenter registry on radiaTion dose estimates of cardiac CT. European Heart Journal, 39(41), 3715–3723.

Einstein, A. J., Pascual, T. N. B., Mercuri, M., Karthikeyan, G., Vitola, J. V., … Abazid, R.
Current worldwide nuclear cardiology practices and radiation exposure: Results from the 65-country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS). European Heart Journal, 36(26), 1689–1696.

Ewid, M., Sherif, H., Allihimy, A. S., Alharbi, S. A., Aldrewesh, D. A., Alkuraydis, S. A., … Abazid, R.
AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Research Notes, 13(1), 178.

Abohamr, S. I., Abazid, R. M., Aldossari, M. A., Amer, H. A., Badhawi, O. S., … Jadaan, M. M.
Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia. Saudi Medical Journal, 41(11), 1217.

Abazid, R. M., Khalaf, H. H., Sakr, H. I., Altorbak, N. A., Alenzi, H. S., Awad, Z. M., … AlMubarak, N.
Effects of Ramadan fasting on the symptoms of chronic heart failure. Saudi Medical Journal, 39(4), 395–401.

Mercuri, M., Pascual, T. N. B., Mahmarian, J. J., Shaw, L. J., Dondi, M., Paez, D., … Abazid, R.
Estimating the reduction in radiation burden from nuclear cardiology through use of stress-only imaging in the United States and worldwide. JAMA Internal Medicine, 176(2), 269–273.

Grzegorz Sobieszek | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Grzegorz Sobieszek | Clinical Trials | Best Researcher Award

Military Hospital Lublin | Poland

Prof. Dr. Grzegorz Sobieszek is an accomplished interventional cardiologist whose career reflects deep clinical expertise, academic commitment, and leadership in advanced cardiovascular procedures. His educational path began with primary and secondary schooling in Lublin, followed by medical studies at the Medical University in Lublin, where he completed both his M.D. and Ph.D. in the Department of Pathophysiology. He went on to obtain full specialization in Internal Medicine and later advanced specialization in Cardiology at WSS Hospital in Lublin, building a strong foundation for his future work in complex cardiovascular care. Dr. Sobieszek has held significant academic and clinical positions, including early work in the Pathophysiology Department and a long tenure at WSS Stefan Kardynał Wyszyński Hospital, culminating in his role as Head of the Cardiology Department and Cathlab at the 1st Military Clinical Hospital in Lublin. A highly respected figure in interventional cardiology, he has more than two decades of hands-on operator experience and over a decade of leadership in managing catheterization laboratories. He is widely recognized as a Chronic Total Occlusion (CTO) expert, performing a high volume of complex CTO interventions annually, utilizing antegrade, retrograde, and ADR techniques, and demonstrating advanced proficiency in CHIP interventions, rotablation, IVL, and physiologic assessment such as FFR, IFR, and microcirculation evaluation. His expertise has earned him invitations for national and international proctoring, live case demonstrations, and recognition for outstanding cases at major CTO forums. Prof. Sobieszek’s academic engagement includes significant contributions to scientific literature, particularly in innovative interventional techniques such as CTO strategies and cutting balloon methods, as well as research on sarcopenia and cachexia in heart failure. He has served as an investigator and principal investigator in multiple clinical trials, contributing to evidence generation and improved patient care. He is also the founder and director of high-level educational workshops, including MASTER CTO Poland, MASTER Calcium, and specialized programs on microcirculation and physiologic assessment. His professional affiliations include membership in the Polish Cardiac Society, Polish Society of Hypertension, European Society of Cardiology, and EAPCI. Throughout his career, he has maintained strong collaborative relationships as an expert and speaker for leading global medical technology companies such as Asahi, Boston Scientific, Abbott, Medtronic, Biotronik, Terumo, Philips-Volcano, and others, reinforcing his position as a key opinion leader in modern interventional cardiology.

Profile: Orcid

Featured Publications

Sliman, H., Sliman, R. K. A., Knaapen, P., Nap, A., Sobieszek, G., & Opolski, M. P. (2025). The role of intravascular imaging in coronary chronic total occlusion PCI: Enhancing procedural success through real-time visualization. Journal of Personalized Medicine, 15(7), Article 318.

Sobieszek, G., Warzyszak, P., & Zięba, B. (2024). Review of management of coronary artery perforation. Journal of Cardiovascular Medicine and Cardiology, Article 000213.

Powrózek, T., Skwarek-Dziekanowska, A., Sobieszek, G., & Małecka-Massalska, T. (2024). Correlation between neutrophil-to-lymphocyte ratio, platelets-to-lymphocyte ratio, C-reactive protein-to-albumin ratio and clinical picture of elderly chronic heart failure patients. Journal of Clinical Medicine, 13(2), Article 433.

Sobieszek, G., Zięba, B., Dworzański, W., Celiński, R., Barbero, U., & Opolski, M. P. (2023). Embolization of perforated coronary artery with a fragment of balloon catheter (cut balloon technique)—Multicenter study. Journal of Cardiovascular Development and Disease, 10(12), Article 496.

Wańha, W., Tomaniak, M., Wańczura, P., Bil, J., Januszek, R., Wolny, R., Opolski, M. P., Kuźma, Ł., Janas, A., Figatowski, T., et al. (2022). Intravascular lithotripsy for the treatment of stent underexpansion: The Multicenter IVL-DRAGON Registry. Journal of Clinical Medicine, 11(7), Article 1779.

Sobieszek, G., Powrózek, T., Skwarek-Dziekanowska, A., & Małecka-Massalska, T. (2021). Clinical significance of TNFRSF1A 36T/C polymorphism in cachectic patients with chronic heart failure. Journal of Clinical Medicine, 10(5), Article 1095.

Łagoda, I., Banasik, K., Sobieszek, G., & Kapka-Skrzypczak, L. (2020). Place of physiotherapy in treatment of myocardial infarction in the context of implementation of the Coordinated Specialist Care Programme. Medycyna Ogólna i Nauki o Zdrowiu, Article 129582.

Sebastian Kelle | Clinical Trials | Distinguished Scientist Award

Published on by Top Pharmaceutical

Prof. Dr. Sebastian Kelle | Clinical Trials | Distinguished Scientist Award

Deutsches Herzzentrum der Charité | Germany

Prof. Dr. Sebastian Kelle is an internationally recognized leader in cardiovascular imaging and one of the most influential experts in cardiac magnetic resonance worldwide. He completed extensive medical training across leading European institutions, including clinical internships in surgery, anesthesiology, and orthopedics, followed by comprehensive medical studies culminating in an M.D. degree. His academic excellence led him to advanced scientific qualifications, including a habilitation in cardiac magnetic resonance at Charité – Universitätsmedizin Berlin, where he worked under the mentorship of eminent cardiovascular scientists. He also earned a doctorate in angiology with supervisory guidance from distinguished faculty at the Martin Luther University Halle-Wittenberg.Prof. Kelle’s career reflects progressive leadership across major cardiovascular research centers. He serves as Head of Cardiovascular Imaging at the German Heart Center and Charité, in addition to leading the Cardiac MRI Department and directing the internationally renowned CMR Academy. His professional pathway includes key roles as professor of cardiac MRI, course director, director of the MRI Core Lab, assistant professor, senior research fellow, and clinical fellow across major German institutions. His global academic contributions were further enriched through prestigious postdoctoral and research fellowships at Johns Hopkins University in the United States.He holds multiple board certifications in cardiology, cardiac MRI, cardiac CT, general internal medicine, and hypertension, along with several Level-III accreditations from leading international societies. Prof. Kelle has served on influential committees and working groups of the German Cardiac Society, the Society for Cardiovascular Magnetic Resonance, and the Charité Doctoral Committee, contributing extensively to scientific development, advocacy, and international outreach.His remarkable achievements have earned him significant professional recognition, including competitive research grants, travel fellowships, society honors, and prestigious awards from leading cardiovascular organizations. Prof. Kelle is also a fellow of several highly respected medical societies, highlighting his prominent standing in the global cardiovascular community.A prolific author, he has contributed to high-impact publications in fields such as myocarditis, inflammatory cardiomyopathies, hemodynamic assessment, myocardial tissue characterization, interstitial fibrosis, coronary endothelial function, and advanced prognostic imaging markers. His scientific insights have shaped current understanding of cardiac MRI’s role in diagnosis, risk stratification, and therapeutic decision-making.

Profile: Scopus

Featured Publications

Anonymous. (2025). Atrial dysfunction: a contrast‑free marker for HFpEF in obese diabetics—insights from comprehensive CMR and serum biomarker analyses. Cardiovascular Diabetology, 24(1), 1‑12. (link unavailable)‑025‑xxxx‑x

Editorial. (2025). Mental stress, significant sex differences, and the substrate for cardiovascular disease: early insights from CMR. Cardiovascular Diabetology, 24(1), 13‑15. (link unavailable)‑025‑yyyy‑y

Anonymous. (2025). Longitudinal effects of lipid‑lowering treatment on high‑risk plaque features and pericoronary adipose tissue attenuation using serial coronary computed tomography. Diagnostics, 15(3), 210‑222. (link unavailable)

Anonymous. (2025). Myocardial strain measurements obtained with fast‑strain‑encoded cardiac magnetic resonance for the risk prediction and early detection of chemotherapy‑related cardiotoxicity compared to left ventricular ejection fraction. Diagnostics, 15(4), 350‑363. (link unavailable)

Anonymous. (2025). Rare isolated transthyretin amyloidosis of the left atrium: step‑wise multi‑modality evaluation by transoesophageal echocardiography, cardiac computed tomography, cardiac magnetic resonance imaging, and single‑photon‑emission computed tomography. European Heart Journal – Cardiovascular Imaging, 26(2), 180‑192. (link unavailable)

Elli Anna Kotsailidi | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Assist. Prof. Dr. Elli Anna Kotsailidi | Clinical Trials | Best Researcher Award

University of Rochester | United States

Assist. Prof. Dr. Elli Anna Kotsailidi is a distinguished academic and clinician specializing in periodontology, implant dentistry, and health professions education. She serves as an Assistant Professor of Clinical Dentistry at the University of Rochester, School of Medicine and Dentistry, and is a key faculty member at the Eastman Institute for Oral Health. With a strong foundation in dental surgery and advanced expertise in periodontal and implant sciences, she has built a remarkable career combining clinical excellence, academic leadership, and educational innovation.Dr. Kotsailidi’s academic journey began with her dental degree from the National and Kapodistrian University of Athens, where she demonstrated early dedication to clinical precision and scientific inquiry. Her pursuit of advanced specialization led her to the Eastman Institute for Oral Health at the University of Rochester, where she completed rigorous training in periodontology and implant dentistry, refining her skills in evidence-based patient care and complex surgical procedures. Further expanding her professional vision, she completed a master’s degree in Health Professions Education at the Warner School of Education, University of Rochester, focusing on curriculum development, equitable teaching, and the enhancement of academic excellence in dental education.Her professional career reflects an unwavering commitment to both patient-centered care and academic mentorship. As Program Director and former Clinic Director in the Department of Periodontology at the Eastman Institute for Oral Health, she has played a pivotal role in shaping clinical programs, overseeing resident training, and ensuring adherence to the highest standards of quality assurance and ethical practice. Her role integrates patient management, surgical supervision, curriculum coordination, and leadership in interdisciplinary dental education involving periodontics, prosthodontics, and general dentistry.Dr. Kotsailidi’s teaching philosophy is deeply rooted in inclusivity, collaboration, and innovation. She has co-directed and taught numerous courses, including Cell Biology of Disease, Introduction to Periodontology, Oral Implantology, ABP Mock Boards, and the Literature Review Series in Periodontics and Dental Implantology. Her approach emphasizes integrative learning, clinical reasoning, and the practical application of scientific knowledge in patient care. She is also an active mentor, serving on research committees for master’s students, guiding systematic reviews and meta-analyses that contribute to evidence-based dentistry and global oral health advancement.

Profile: Orcid

Featured Publications

Umbrio, L. R. N., Pham, H. M., Barmak, A. B., Assery, N., & Kotsailidi, E. A. (2025). Association between selective serotonin reuptake inhibitors and the periodontal status: A systematic review and meta-analysis of observational clinical studies. Evidence-Based Dentistry.

Benzaquen, S. I., Torabi Ardakani, M., Tsigarida, A., Ercoli, C., Barmak, B., Chochlidakis, K. M., & Kotsailidi, E. A. (2025). Biologic complications with removable partial dentures assisted by short implants: A 34-month pilot randomized controlled clinical trial. The Journal of Prosthetic Dentistry.

Kotsailidi, E. A., Johnson, L., Burns, C., Rossouw, P. E., & Michelogiannakis, D. (2025). Surgically facilitated orthodontics with clear aligners for severe malocclusion and gingival recessions. Clinical Advances in Periodontics.

Burns, C., Kotsailidi, E. A., Alshuraim, F., Dadjoo, S., Tzouma, K., Pedrinaci, I., Rossouw, P. E., & Michelogiannakis, D. (2024). Interdisciplinary orthodontic treatment with digitally-guided autotransplantation in a patient with a missing permanent maxillary left lateral incisor and a supernumerary mandibular incisor. AJO-DO Clinical Companion.

Meixian Zhang | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Meixian Zhang | Clinical Trials | Best Researcher Award

Director at Taizhou Hospital of Zhejiang Province | China

Dr. Meixian Zhang is an Associate Researcher and Master’s Supervisor at Wenzhou Medical University. With a Ph.D. in Public Health, she specializes in clinical epidemiology, evidence-based medicine, and obesity research. Her career is marked by over 35 SCI journal publications and leadership in multiple national and provincial research projects. She is deeply committed to tackling childhood obesity through genetic and dietary studies. With a passion for translational health research and mentoring, Dr. Zhang has earned recognition through innovation, impactful findings, and dedicated academic service. She continues to push boundaries in the fight against obesity-related health risks.

Publication Profile 

Orcid

Education

Dr. Zhang Meixian earned her Ph.D. in Public Health, specializing in childhood obesity and molecular epidemiology. Her academic journey began with a strong foundation in clinical medicine and public health, followed by doctoral research focusing on genetic predisposition to pediatric adiposity. She has been trained extensively in clinical epidemiology, biostatistics, and molecular genetics. Her postgraduate training enabled her to explore multifaceted aspects of obesity-related metabolic disorders and the implementation of evidence-based interventions. The academic rigor and scientific integrity developed during her education continue to guide her ongoing contributions to translational research and public health education.

Experience

With over a decade of research and academic experience, Dr. Zhang currently serves as an Associate Researcher at Wenzhou Medical University. She has supervised graduate students and led numerous scientific projects as principal investigator. Her work bridges molecular epidemiology, public health policy, and clinical research. She’s received major grants from the National Natural Science Youth Fund and Zhejiang provincial programs. She has also contributed to high-impact studies on obesity, SNPs, and weight management. Through editorial appointments and cross-institution collaborations, she continues to expand the reach of her research across China and the global scientific community.

Awards 

Dr. Zhang has received significant recognition for her contributions to medical research. She has been awarded grants from the National Natural Science Youth Fund and the Basic Public Welfare Research Program of Zhejiang Province as a Principal Investigator. Additionally, she has secured two provincial-level medical and science grants and one from the Taizhou Science and Technology Council. Her innovative research has led to two authorized national invention patents and one software copyright. These accolades underscore her scientific excellence and translational impact in obesity and metabolic health, positioning her as a leading figure in evidence-based public health research.

Research Focus 

Dr. Zhang’s research centers on childhood obesity, metabolic syndrome, and genetic susceptibility markers. She investigates the role of leptin, adiponectin, FTO gene variants, and other biomarkers in the development of obesity. Her work bridges molecular epidemiology with clinical nutrition, validating interventions such as intermittent fasting, calorie restriction, and meal replacements. Additionally, she explores single-nucleotide polymorphisms (SNPs) and their regulatory functions in metabolic pathways. Dr. Zhang’s interdisciplinary approach integrates public health, genomics, and preventive medicine, aiming to deliver targeted health strategies for pediatric populations in China and globally.

Top Publications

Title: Willingness of Older Adults with Chronic Diseases to Receive a Booster Dose of Inactivated Coronavirus Disease 2019 Vaccine: A Cross-Sectional Study in Taizhou
Year: 2025

Conclusion

Dr. Zhang Meixian’s academic rigor, originality, and focused contributions in combating obesity through evidence-based and genetics-informed approaches position her as an outstanding candidate for the Best Researcher Award. Her ability to translate complex research into meaningful public health solutions, combined with her strong record of funding, publications, and innovation, make her a worthy and impactful recipient of this recognition. With minor strategic advancements, her global influence is poised to grow even further.

Dr. Minoo Moghimi|Clinical Trials|Best Researcher Award

Published on by Top Pharmaceutical

Dr. Minoo Moghimi|Clinical Trials|Best Researcher Award

Dr. Minoo Moghimi at Mazandaran University of Medical Sciences,Iran

PROFILE  

Google scholar

 

Early Academic Pursuits 🎓

Minoo Moghimi embarked on her academic journey with a solid foundation in the National Organization for Development of Exceptional Talents, where she obtained her high school diploma in Yazd (2007-2011). This formative education laid the groundwork for her entrance into the field of pharmacy, where she pursued a PharmD at Yazd University of Medical Sciences from 2011 to 2018. Her early involvement with the faculty research committee highlighted her dedication to the field of pharmacotherapy, showcasing a keen interest in advancing pharmaceutical science right from the start.

Moghimi’s PharmD thesis focused on developing porous microencapsulated probiotics using a spray freeze drying technique. This innovative research emphasized the importance of drug formulation technology and aimed at enhancing probiotic viability. The success of this project led to a patent, marking a significant achievement in her early career and reflecting her capability to contribute meaningfully to pharmaceutical innovation.

Professional Endeavors 🏥

After completing her PharmD, Moghimi chose to channel her expertise into clinical applications by entering the Clinical Pharmacy Residency Program at Mazandaran University of Medical Sciences in 2018. This decision was driven by her passion for directly assessing drug effects in real-world patient scenarios. Throughout her residency, she demonstrated a profound dedication to clinical pharmacy, actively participating in research programs and engaging in numerous projects with a strong focus on clinical trials.

Her professional trajectory took a pivotal turn in 2020 during the COVID-19 pandemic when she contributed to the DISCOVER trial. This was a large-scale, randomized clinical trial involving over 1,000 patients, evaluating the efficacy of sofosbuvir and daclatasvir in treating hospitalized COVID-19 patients. The findings, published in the Journal of Antimicrobial Chemotherapy, were instrumental in understanding potential treatment options during the pandemic, reflecting her commitment to evidence-based clinical practice.

Moghimi’s professional expertise also extends beyond infectious diseases, as she has been involved in designing and implementing clinical trials in oncology, gynecology, and dentistry. Her diverse research portfolio underscores her adaptability and readiness to tackle multifaceted clinical challenges.

Contributions and Research Focus 📚

Minoo Moghimi’s primary research focus lies in managing chemotherapy-induced adverse effects, a critical area that significantly impacts cancer patient care. Her ongoing residency thesis, “Evaluation of the Efficacy and Safety of the Addition of Lacosamide to Duloxetine in the Treatment of Taxane-Induced Peripheral Neuropathy: A Randomized Double-Blind Placebo-Controlled Trial,” reflects this focus. Through this project, she aims to mitigate the debilitating side effects associated with chemotherapy, thus enhancing the quality of life for cancer patients.

In addition to her research in oncology, Moghimi has actively contributed to pharmacotherapy in critical care settings, clinical nutrition management, and drug-drug interaction management. Her ability to design comprehensive clinical trials is supported by her skills in clinical trial design, protocol development for critical medications, and medication reconciliation—skills that have proven vital in her multidisciplinary approach to patient care.

Moghimi’s contributions are not limited to clinical environments; she also engages in academic service. As a reviewer for respected journals like Pharmaceutical and Biomedical Research Journal (PBR) and Annals of Clinical and Medical Case Reports, she evaluates research, ensuring high standards in pharmacotherapy literature.

Accolades and Recognition 🏅

Throughout her academic and professional career, Minoo Moghimi has achieved several notable milestones. Her early achievement in patenting her thesis project during her PharmD studies reflects her commitment to innovation. During the COVID-19 pandemic, her role in the DISCOVER trial received significant recognition, as the study’s outcomes played a crucial role in informing clinical practices and treatment protocols for COVID-19 patients.

Impact and Influence 🌍

Minoo Moghimi’s research has had a tangible impact on the fields of clinical pharmacy and pharmacotherapy. Her work in chemotherapy-induced adverse effects, particularly taxane-induced peripheral neuropathy, aims to provide oncologists with better tools to manage the side effects of cancer treatments. By focusing on this critical aspect of cancer care, she is not only advancing research but also directly contributing to patient well-being, showcasing the transformative power of targeted pharmacotherapy.

Her involvement in critical care pharmacotherapy, nutrition management, and drug-drug interaction management demonstrates a holistic approach to patient care, where she considers various factors influencing therapeutic outcomes. This multidisciplinary expertise positions her as a key contributor to advancing patient-centered care in clinical settings.

Legacy and Future Contributions 🌟

Looking ahead, Minoo Moghimi aims to continue her work at the intersection of research and clinical practice. Her focus on chemotherapy-induced adverse effects, critical care, and nutrition management indicates a commitment to advancing patient care through evidence-based research. As a Board Certified Pharmacotherapy Specialist, her goal is to bridge the gap between research and clinical applications, ensuring that pharmacotherapy evolves in response to patient needs.

In the future, Moghimi plans to expand her research into novel drug therapies, aiming to develop innovative interventions for managing complex clinical conditions. Her dedication to the peer-review process reflects her intention to contribute to the scientific community by ensuring the dissemination of accurate and impactful research findings.

Skills and Technological Expertise 💻

Minoo Moghimi possesses a diverse skill set encompassing clinical trial design, research management, and critical care pharmacotherapy. Her expertise extends to protocol development for high-risk drugs, clinical nutrition, and drug-drug interaction management. In terms of technical skills, she is proficient with software like GraphPad Prism, Endnote, and MS Office—tools that are essential for managing data, conducting statistical analysis, and organizing research findings.

Research Interests and Aspirations 🔬

Her primary research interests revolve around chemotherapy-induced adverse effects, a field that holds immense potential for improving cancer care outcomes. Moghimi is also dedicated to critical care pharmacotherapy and nutrition management, fields where she hopes to make significant contributions in the future. Her aspiration is to develop strategies and guidelines that healthcare professionals can utilize to optimize treatment outcomes in complex clinical scenarios.

Conclusion 🎯

Minoo Moghimi’s journey from a dedicated pharmacy student to a Board Certified Pharmacotherapy Specialist is marked by a strong academic foundation, substantial research contributions, and a commitment to improving patient care. Her work has already left an indelible mark on the clinical pharmacy landscape, and her ongoing projects promise to further enhance therapeutic approaches in critical care and oncology. Moghimi’s career is a testament to the profound impact that dedicated research, clinical expertise, and a patient-centered approach can have in advancing healthcare.

🎓Publication 

A Narrative Review on Adverse Effects of Dasatinib With a Focus on Pharmacotherapy of Dasatinib-Induced Pulmonary Toxicities

  • Authors   :Zahra Nekoukar, Minoo Moghimi, Ebrahim Salehifar
  • Journal    :Blood Research
  • Year         :2021

Evaluation of the Effect of Sofosbuvir and Daclatasvir in Hospitalised COVID-19 Patients: A Randomized Double-Blind Clinical Trial (DISCOVER)

  • Authors   : Sara Mobarak, Mehdi Salasi, Ahmad Hormati, Javad Khodadadi, Masood Ziaee, Farshid Abedi, Azadeh Ebrahimzadeh, Zohreh Azarkar, Fariborz Mansour-Ghanaei, Farahnaz Joukar, Sara Yeganeh, Tofigh Yaghubi Kalurazi, Mohammadreza Naghipour, Zeinab Mehrabi, Amir Reza Bahadori, Shoeleh Yaghoubi, Rohollah Moslemi, Hamideh Abbaspour Kasgari, Hafez Fakheri, Minoo Moghimi, Amir Mohammad Shabani, Zahra Nekoukar, Farhang Babamahmoodi, 
  • Year         :2025

Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with moderate COVID-19, A

  • Authors   :Zahra Nekoukar , Shahram Ala, Siavash Moradi, Andrew Hill, Ali Reza Davoudi Badabi, Ahmad Alikhani, Shahriar Alian, Minoo Moghimi, Amir Mohammad Shabani, Hamideh Abbaspour Kasgari
  • Journal    :Iranian Journal of Pharmaceutical Research
  • Year         :2021

Suicide attempt using zinc phosphide rodenticide: A case report and literature review

  • Authors   :Zahra Nekoukar, Minoo Moghimi, Kimia Rasouli, Aref Hoseini, Zakaria Zakariaei, Rabeeh Tabaripour, Mahdi Fakhar, Elham Sadat Banimostafavi 
  • Journal    : Clinical case reports
  • Year         :2021

Prevalence of Thromboembolic Events, Including Venous Thromboembolism and Arterial Thrombosis, in Patients with COVID-19: A Systematic Review with Meta-Analysis

  • Authors   :Babak Bagheri, Abbas Alipour, Mojtaba Yousefi, Rozita Jalalian, Minoo Moghimi, Mahsa Mohammadi, Negar Hassanpour, Mohammadreza Iranian
  • Journal    :Tehran University of Medical Sciences
  • Year         :2023